Dr. Run Wang, MD

Dr. Wang practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Wang's NPI, 1386677268, was assigned on July 7, 2006. Dr. Wang graduated from Southeast University Medical College in 1983. Dr. Wang holds Texas license L5176.

Dr. Wang's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Wang's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. Dr. Wang is also affiliated with John Sealy Hospital. The medical group on file is UT Physicians. Dmand AI also links Dr. Wang to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wang practices, 4 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Wang's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Wang is board certified in urology by the American Board of Urology. Dmand AI has Dr. Wang's licenses on file in 10 states: Texas, Florida, Arizona, Georgia, Oklahoma, Tennessee, Alabama, Louisiana, Mississippi and Washington.

Dmand AI lists enlarged prostate, erectile dysfunction, prostate cancer, prostate surgery, testicular dysfunction and urinary endoscopy among the conditions Dr. Wang treats.

CMS data shows 687 Medicare services from Dr. Wang across 7 procedure codes in 2024, for 452 Medicare patients. Medicare paid $63,743 for them.

CMS counts 452 Medicare patients who saw Dr. Wang in 2024. The largest group is 65 to 74, with 326 patients. 75% of them have cancer, and 75% have high cholesterol. 3% are also on Medicaid. Their average risk score is 1.28, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Wang's median patient age at 70, with 0% women.

In 2024, Dr. Wang wrote 251 Medicare Part D claims for 97 patients. 94% of them were for generic drugs. CMS names the drug for 212 of them, across 6 drugs with 11 or more claims each, at $11,094 in total drug cost. In 2023, CMS named 365 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Wang for performance year 2024, reported as part of a group. Dr. Wang accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Wang as offering telehealth.

Dmand AI links 140 papers to Dr. Wang, published from 2006 to 2025. 2021 was the busiest year, with 9. The most frequent topics are Erectile Dysfunction, Penis and Penile Prosthesis. Dr. Wang has published most often in Asian J Androl. Dr. Wang's most frequent co-authors are Ouida L. Westney, MD, Travis Paul Green, MD and Steven E. Canfield, MD.

Dmand AI links Dr. Wang to 1 clinical trial. Conditions studied include Erectile Dysfunction and Sexual Dysfunctions, Psychological.

CMS Open Payments shows 552 general payments to Dr. Wang from 31 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 60% of the total. Boston Scientific Corporation paid the most, $148,494.

Dmand AI lists 2 awards for Dr. Wang, most recently ACS Fellow in 2012.

Dr. Wang graduated from Southeast University Medical College in 1983. Dr. Wang is a member of ACS.

Dr. Wang is in network with 21 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.